Desmopressin nasal spray to decrease the bleeding complications in percutaneous kidney biopsy

Desmopressin nasal spray to decrease the bleeding complications in percutaneous kidney biopsy: a randomized controlled trial - DESMOPRESSIN-BIOPSY Trial

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/12/029747

Enrollment

160

Registered

2020-12-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N17-N19- Acute kidney failure and chronic kidney disease Health Condition 2: N00-N08- Glomerular diseases Health Condition 3: N10-N16- Renal tubulo-interstitial diseases

Interventions

Intervention1: Desmopressin Arm: Desmopressin nasal spray 4 puff given 30 min before renal biopsy Control Intervention1: Control Arm: Saline nasal spray 4 puff given 30 min before renal biopsy

Eligibility

Inclusion criteria

Inclusion criteria: 1.Blood pressure 2. Normal coagulation parameters and platelet count

Exclusion criteria

Exclusion criteria: Graft kidney biopsy, Patients on antiplatelets, Poorly controlled hypertension, Hydro/pyonephrosis, Any form of coagulation disorder

Design outcomes

Primary

Measure	Time frame
Post-biopsy Bleeding Complications, Presence of hematoma and its sizeTimepoint: 12 hours and 24 hours after biopsy	—

Secondary

Measure	Time frame
Variation in blood pressure 12 hours before and upto 24 hour after kidney biopsy Timepoint: 24 hours after biopsy	—

Countries

India

Contacts

Public ContactDr Vineet Behera

Dept of Internal Medicine, INHS Asvini

vineetbeheraaiims@gmail.com02222143992

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026